Australian government funds international CAR-T clinical trials for children

By Elena MacLeod · September 21, 2026, 11:45 PM · 3 mins read

A new five million dollar grant from the Australian Government will bring international CAR-T clinical trials for childhood cancer to Australia, reducing the need for families to seek treatment overseas.

For many Australian families dealing with childhood cancer, traveling overseas for clinical trials has often been the only option. That is set to change. The Australian Government has committed five million dollars to bring international CAR-T clinical trials for children and young people to Australia.

This funding comes from the Medical Research Future Fund (MRFF) and is the first investment under the MRFF’s Australian Cancer Research Program. The program aims to coordinate cancer research across the country, but this initial grant is focused on building CAR-T clinical trial capacity in Australia. According to the Children’s Cancer Institute, the five million dollars will be distributed over five years to support Australia’s involvement in the LifeArc Worldwide CAR-T Pathfinder Trial and the Paediatric Cell Therapy Accelerator. The goal is to give young patients access to the latest global cancer treatments without leaving home.

The initiative is designed so that children and young people in Australia can participate in international CAR-T clinical trials without the need to travel overseas.
Children’s Cancer Institute

The government expects the grant process to open in June 2027, with funding available from the 2027-28 period. The main aim is to ease the burden on families who would otherwise have to travel abroad for CAR-T therapies. As reported in a Mirage News update, this is the first investment under the new Australian Cancer Research Program MRFF, with the grant process expected to launch in mid-2027.

Bringing these international trials to Australia means young patients can stay closer to their families and familiar healthcare teams. Professor Louis Chesler of the Children’s Cancer Institute welcomed the decision, saying it will give Australian children access to "the best the world has to offer" in cancer treatment.

Details about the specific trials and international partners are still to come, but the government’s move is a clear investment in research infrastructure and patient access. The MRFF’s Australian Cancer Research Program is positioning itself as a national coordinator, aiming to raise the standard of cancer research across Australia. The international program mentioned by the Children’s Cancer Institute includes both the LifeArc Worldwide CAR-T Pathfinder Trial and the Paediatric Cell Therapy Accelerator, showing Australia’s involvement in a broader global research network.

The international program includes both the LifeArc Worldwide CAR-T Pathfinder Trial and the Paediatric Cell Therapy Accelerator, reflecting a broader cooperation with a global clinical research network rather than a single trial site.
Children’s Cancer InstituteOrganization

This five million dollar commitment is intended to close the gap between Australian patients and the latest CAR-T therapies worldwide. If carried out as planned, it could change how childhood cancer clinical trials are run in Australia and set the stage for future investments in research and patient care.

Topics:

Biotechnology Newsroom

Elena MacLeod

Elena MacLeod is Clinical Biotechnology Editor at GenoMethods, covering CAR-T, engineered cell therapies, gene therapy, clinical trials, cancer immunology and regulatory developments. Her evidence-first reporting focuses on trial design, patient populations, safety, efficacy, response durability and the limitations that determine how early clinical results should be interpreted.